Extrait

Determine the objective response rate (ORR: complete plus partial responses) for HKI-272 in subjects with advanced non-small cell lung cancer.

Critère d'inclusion

• Agents targeting the epidermal growth factor receptor (EGFR) have made a major impact on the treatment of advanced NSCLC. EGFR tyrosine kinase inhibitors (TKI) erlotinib and gefitinib elicit a dramatic response in some patients with relapsed NSCLC, but resistance to that therapy is significant. Recently it was reported that irreversibly-binding EGFR-TKIs may prove highly effective in patients with EGFR activation mutations, including tumors that have become resistant to erlotinib or gefitinib

Liens

• ictrp
• ictrp
• euctr
• euctr